Aquestive Therapeutics (AQST) EBIT (2017 - 2026)

Aquestive Therapeutics' EBIT history runs 10 years deep, the most recent figure standing at -$4.2 million for Q1 2026.

• In Q1 2026, EBIT rose 78.29% year-over-year to -$4.2 million; the TTM figure through Mar 2026 stood at -$55.9 million (down 35.72% YoY), while the FY2025 annual figure was -$71.1 million, down 130.9% from the prior year.
• EBIT was -$4.2 million for Q1 2026 at Aquestive Therapeutics, up from -$28.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $55000.0 in Q2 2024 to a low of -$28.8 million in Q4 2025.
• Historically, EBIT has averaged -$9.6 million across 5 years, with a median of -$9.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: EBIT soared 101.31% in 2024, then slumped 20769.09% in 2025.
• A 5-year view of EBIT shows it stood at -$10.7 million in 2022, then soared by 63.49% to -$3.9 million in 2023, then sank by 247.2% to -$13.6 million in 2024, then slumped by 112.38% to -$28.8 million in 2025, then surged by 85.42% to -$4.2 million in 2026.
• The last three EBIT figures came in at -$4.2 million (Q1 2026), -$28.8 million (Q4 2025), and -$11.5 million (Q3 2025), per Business Quant data.